• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Prognosis after hepatic resection in patients with hepatocellular carcinoma, estimated on the basis of the morphometric indices.

作者信息

Kawai Y, Takeshige K, Nunome M, Kuroda H, Suzuki H, Banno K, Koide T, Kobayashi H, Owa Y, Koike A

机构信息

First Department of Surgery, Aichi Medical University, Japan.

出版信息

Cancer Chemother Pharmacol. 1994;33 Suppl:S24-8. doi: 10.1007/BF00686663.

DOI:10.1007/BF00686663
PMID:8137480
Abstract

To determine whether the morphometric indices of hepatocellular carcinoma (HCC) correlated with the prognoses, the microscopic morphometric values for 84 HCC cases treated by hepatic resection were studied using an image analyzer in relation to the survival rate and the gross classification. The mean survival time (MST) was 58 months in cases with a nucleocytoplasmic area ratio (N/C) of less than 0.28; this was significantly longer than the 38-month MST in cases with an N/C of more than 0.28 (P < 0.05). In stage III disease, the MST for cases with an N/C of less than 0.28 was 63 months, which was significantly longer than the MST of 13 months for cases with an N/C of more than 0.28. After relatively noncurative hepatic resection, the MST for cases with an N/C of less than 0.28 was 49 months, and this was significantly longer than the MST of 8 months for cases with an N/C of more than 0.28. The MST was 71 months for cases with a coefficient of variance of the nuclear form factor (NCV) of less than 5.5%, which was significantly longer than the MST of 33 months for cases with an NCV of more than 5.5% (P < 0.05). In stage III disease, the MST was 69 months for cases with an NCV of less than 5.5%, and this was significantly longer than the MST of 29 months for cases with an NCV of more than 5.5% (P < 0.05). In cases with an N/C of less than 0.28, 18% had vascular invasion and 38% had intrahepatic metastases, whereas in those with an N/C of more than 0.28, 62% had vascular invasion and 67% had intrahepatic metastases (P < 0.01, P < 0.05). Based on the results of these morphometric studies on HCC cases treated by hepatic resection, N/C and NCV may be useful as prognostic factors.

摘要

相似文献

1
Prognosis after hepatic resection in patients with hepatocellular carcinoma, estimated on the basis of the morphometric indices.
Cancer Chemother Pharmacol. 1994;33 Suppl:S24-8. doi: 10.1007/BF00686663.
2
Long-term results after resection of hepatocellular carcinoma: experience of 480 cases.肝细胞癌切除术后的长期结果:480例经验
Hepatogastroenterology. 1993 Aug;40(4):328-32.
3
Analysis of factors affecting outcome after hepatectomy of patients with liver cirrhosis and small hepatocellular carcinoma.肝硬化合并小肝细胞癌患者肝切除术后影响预后因素的分析
Eur J Surg. 1998 Jul;164(7):513-9. doi: 10.1080/110241598750005868.
4
Efficacy of major hepatectomy for large hepatocellular carcinoma.大肝癌肝切除术的疗效
Hepatogastroenterology. 2009 May-Jun;56(91-92):768-72.
5
Significance of hepatic resection and adjuvant hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombus in the first branch of portal vein and the main portal trunk: a project study for hepatic surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery.对于第一肝门部和主门静脉分支的肝癌合并门静脉癌栓,肝切除术和辅助性肝动脉灌注化疗的意义:日本肝胆胰外科学会肝脏外科研讨会项目研究。
J Hepatobiliary Pancreat Sci. 2018 Sep;25(9):395-402. doi: 10.1002/jhbp.574. Epub 2018 Sep 4.
6
Hepatic resection for hepatocellular carcinoma in diameter of > or = 10 cm.直径大于或等于10厘米的肝细胞癌的肝切除术
Hepatogastroenterology. 2002 Mar-Apr;49(44):518-23.
7
Prognostic factors of hepatic resection for hepatocellular carcinoma with cirrhosis: univariate and multivariate analysis.肝硬化肝细胞癌肝切除的预后因素:单因素和多因素分析
J Surg Oncol. 2002 Dec;81(4):195-202. doi: 10.1002/jso.10178.
8
Prognostic factors for survival after hepatic resection of early hepatocellular carcinoma in HBV-related cirrhotic patients.HBV 相关肝硬化患者行肝切除术后早期肝细胞癌的生存预后因素。
Clin Res Hepatol Gastroenterol. 2016 Sep;40(4):418-27. doi: 10.1016/j.clinre.2015.12.007. Epub 2016 Jan 25.
9
Cirrhosis and microvascular invasion predict outcomes in hepatocellular carcinoma.肝硬化和微血管侵犯可预测肝细胞癌的预后。
ANZ J Surg. 2013 May;83(5):331-5. doi: 10.1111/j.1445-2197.2012.06196.x. Epub 2012 Sep 3.
10
Step classification is useful for the determination of indications for systematized hepatectomy in hepatocellular carcinoma.步骤分类对于确定肝细胞癌中系统化肝切除术的适应症很有用。
J Hepatobiliary Pancreat Surg. 2005;12(5):371-7. doi: 10.1007/s00534-005-1003-2.

引用本文的文献

1
Overexpression of the far upstream element binding protein 1 in hepatocellular carcinoma is required for tumor growth.肝癌中上游远元件结合蛋白1的过表达是肿瘤生长所必需的。
Hepatology. 2009 Oct;50(4):1121-9. doi: 10.1002/hep.23098.

本文引用的文献

1
Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.原发性肝癌:48900例尸检中的100例研究。
Cancer. 1954 May;7(3):462-503. doi: 10.1002/1097-0142(195405)7:3<462::aid-cncr2820070308>3.0.co;2-e.
2
Biopsy diagnosis of well-differentiated hepatocellular carcinoma based on new morphologic criteria.
Hepatology. 1989 May;9(5):751-5. doi: 10.1002/hep.1840090516.
3
Increased DNA synthetic potency of hepatocytes in cirrhotic patients may indicate a super-high risk for hepatocellular carcinoma.肝硬化患者肝细胞的DNA合成能力增强可能表明其患肝细胞癌的风险极高。
Jpn J Med. 1990 Jul-Aug;29(4):373-8. doi: 10.2169/internalmedicine1962.29.373.
4
The potential role of postoperative hepatic artery chemotherapy in patients with high-risk hepatomas.术后肝动脉化疗在高危肝癌患者中的潜在作用。
Ann Surg. 1991 Mar;213(3):222-6. doi: 10.1097/00000658-199103000-00007.
5
Significance of multidisciplinary therapy for hepatocellular carcinoma.多学科治疗对肝细胞癌的意义。
Cancer Chemother Pharmacol. 1992;31 Suppl:S13-9. doi: 10.1007/BF00687098.
6
Risk factors linked to tumor recurrence of human hepatocellular carcinoma after hepatic resection.肝切除术后人类肝细胞癌肿瘤复发的相关危险因素。
Hepatology. 1992 Dec;16(6):1367-71. doi: 10.1002/hep.1840160611.
7
Hepatocellular carcinoma: treatment with percutaneous ethanol injection and transcatheter arterial embolization.肝细胞癌:经皮乙醇注射和经导管动脉栓塞治疗
Radiology. 1992 Nov;185(2):457-60. doi: 10.1148/radiology.185.2.1329143.
8
Comparison of hepatectomy and transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma: necessity for prospective randomized trial.肝切除术与经动脉化疗栓塞术治疗肝细胞癌的比较:前瞻性随机试验的必要性
Hepatology. 1992 Sep;16(3):702-6. doi: 10.1002/hep.1840160314.
9
Limitations of current preoperative liver imaging techniques for intrahepatic metastatic nodules of hepatocellular carcinoma.当前用于肝细胞癌肝内转移结节的术前肝脏成像技术的局限性。
Hepatology. 1992 Sep;16(3):694-701. doi: 10.1002/hep.1840160313.
10
Predictive factors for intrahepatic recurrence of hepatocellular carcinoma after partial hepatectomy.肝细胞癌肝部分切除术后肝内复发的预测因素
Cancer. 1992 Feb 15;69(4):913-9. doi: 10.1002/1097-0142(19920215)69:4<913::aid-cncr2820690413>3.0.co;2-t.